Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 8.84% is 138% above its 5-year average of -23.02%, near the high end of its 5-year range (-97.88%–24.60%).
As of the fiscal period ended Tuesday, June 30, 2026. 47.21% below its 12-month average of 16.74%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 8.84%.
RETURN ON INVESTED CAPITAL (ROIC)
8.84%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
16.74%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
3.05%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-23.02%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-46.20%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
-55.78%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
-47.21%
CURRENT VS 3Y AVG
+190.20%
CURRENT VS 5Y AVG
+138.40%
CURRENT VS 10Y AVG
+119.13%
CURRENT VS 15Y AVG
+115.84%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.80%
median of 698 covered companies
CURRENT VS SECTOR MEDIAN
+126.15%
vs the sector median at left
Niagen Bioscience Inc
Market Cap
$214.24M
Return on Invested Capital (ROIC)
8.84%
TTM Avg
16.74%
3Y Avg
3.05%
5Y Avg
-23.02%
Market Cap
$214.44M
Return on Invested Capital (ROIC)
-70.80%
TTM Avg
-76.09%
3Y Avg
-51.87%
5Y Avg
-42.00%
Market Cap
$214.16M
Return on Invested Capital (ROIC)
26.14%
TTM Avg
3.79%
3Y Avg
-12.27%
5Y Avg
-17.37%
Market Cap
$215.94M
Return on Invested Capital (ROIC)
19.13%
TTM Avg
15.37%
3Y Avg
31.31%
5Y Avg
44.42%
Market Cap
$214.35M
Return on Invested Capital (ROIC)
-43.74%
TTM Avg
-105.81%
3Y Avg
-81.36%
5Y Avg
-65.49%
Market Cap
$217.61M
Return on Invested Capital (ROIC)
-71.04%
TTM Avg
-53.65%
3Y Avg
-40.34%
5Y Avg
-35.55%
Market Cap
$207.87M
Return on Invested Capital (ROIC)
-33.10%
TTM Avg
-20.50%
3Y Avg
-16.94%
5Y Avg
-23.40%
Market Cap
$207.34M
Return on Invested Capital (ROIC)
14.99%
TTM Avg
15.04%
3Y Avg
13.17%
5Y Avg
12.12%
Market Cap
$223.25M
Return on Invested Capital (ROIC)
-36.49%
TTM Avg
-7.39%
3Y Avg
-25.88%
5Y Avg
-24.07%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $214.24M | 8.84% | 16.74% | 3.05% | -23.02% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.44M | -70.80% | -76.09% | -51.87% | -42.00% |
| Compugen Ltd. (CGEN)vs › | $214.16M | 26.14% | 3.79% | -12.27% | -17.37% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.94M | 19.13% | 15.37% | 31.31% | 44.42% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | -43.74% | -105.81% | -81.36% | -65.49% |
| Alector, Inc. (ALEC)vs › | $217.61M | -71.04% | -53.65% | -40.34% | -35.55% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.87M | -33.10% | -20.50% | -16.94% | -23.40% |
| Pro-Dex, Inc. (PDEX)vs › | $207.34M | 14.99% | 15.04% | 13.17% | 12.12% |
| Keros Therapeutics, Inc. (KROS)vs › | $223.25M | -36.49% | -7.39% | -25.88% | -24.07% |
| Electra Therapeutics Inc. (ETRA)vs › | $202.90M | N/A | N/A | N/A | N/A |
ROIC
8.8%
ROE
19.4%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 8.84% |
| 2026-03-31 | 11.35% |
| 2025-12-31 | 15.61% |
| 2025-09-30 | 24.60% |
| 2025-06-30 | 23.30% |
| 2025-03-31 | 21.16% |
| 2024-12-31 | 14.82% |
| 2024-09-30 | 1.15% |
| 2024-06-30 | -6.36% |
| 2024-03-31 | -12.60% |
| 2023-12-31 | -16.30% |
| 2023-09-30 | -20.20% |
| 2023-06-30 | -25.78% |
| 2023-03-31 | -36.40% |
| 2022-12-31 | -51.48% |
| 2022-09-30 | -77.75% |
| 2022-06-30 | -97.88% |
| 2022-03-31 | -80.16% |
| 2021-12-31 | -67.30% |
| 2021-09-30 | -65.22% |
| 2021-06-30 | -46.75% |
| 2021-03-31 | -43.31% |
| 2020-12-31 | -90.73% |
| 2020-09-30 | -92.76% |
| 2020-06-30 | -97.59% |
| 2020-03-31 | -136.29% |
| 2019-12-31 | -124.29% |
| 2019-09-30 | -95.53% |
| 2019-06-30 | -106.83% |
| 2019-03-31 | -125.65% |
| 2018-12-31 | -119.36% |
| 2018-09-30 | -98.97% |
| 2018-06-30 | -68.64% |
| 2018-03-31 | -48.57% |
| 2017-12-31 | -29.97% |
| 2017-09-30 | -28.11% |
| 2017-06-30 | -28.02% |
| 2017-03-31 | -43.18% |
| 2016-12-31 | -20.43% |
| 2016-09-30 | -10.80% |
| 2016-06-30 | -1.84% |
| 2016-03-31 | -6.79% |
| 2015-12-31 | -20.15% |
| 2015-09-30 | -20.65% |
| 2015-06-30 | -30.42% |
| 2015-03-31 | -64.49% |
| 2014-12-31 | -77.39% |
| 2014-09-30 | -94.64% |
| 2014-06-30 | -111.00% |
| 2014-03-31 | -91.85% |
| 2013-12-31 | -71.34% |
| 2013-09-30 | -146.23% |
| 2013-06-30 | -74.56% |
| 2013-03-31 | -122.01% |
| 2012-12-31 | -272.42% |
| 2012-09-30 | -224.73% |
| 2012-06-30 | -223.73% |
| 2012-03-31 | -128.94% |
| 2011-12-31 | -268.69% |
| 2011-09-30 | -127.52% |
| 2011-06-30 | -97.48% |
| 2011-03-31 | -58.97% |
| 2010-12-31 | -37.58% |
| 2010-09-30 | -21.93% |
| 2010-06-30 | -8.80% |
| 2010-03-31 | -31.20% |
| 2009-12-31 | -64.80% |
| 2009-09-30 | -105.37% |
| 2009-06-30 | -131.87% |
| 2009-03-31 | -132.34% |
